John E. Sylvester

2.7k total citations
38 papers, 1.9k citations indexed

About

John E. Sylvester is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, John E. Sylvester has authored 38 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 16 papers in Radiation and 7 papers in Surgery. Recurrent topics in John E. Sylvester's work include Prostate Cancer Diagnosis and Treatment (31 papers), Prostate Cancer Treatment and Research (27 papers) and Advanced Radiotherapy Techniques (16 papers). John E. Sylvester is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (31 papers), Prostate Cancer Treatment and Research (27 papers) and Advanced Radiotherapy Techniques (16 papers). John E. Sylvester collaborates with scholars based in United States, Canada and United Kingdom. John E. Sylvester's co-authors include John C. Blasko, Peter Grimm, William Cavanagh, R. Meier, Gregory S. Merrick, Haakon Ragde, Robert W. Galbreath, Gerald M. Kenny, Judith A. Malmgren and Stanley L. Liauw and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

John E. Sylvester

32 papers receiving 1.8k citations

Peers

Countries citing papers authored by John E. Sylvester

Since Specialization

Citations

This map shows the geographic impact of John E. Sylvester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Sylvester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Sylvester more than expected).

Fields of papers citing papers by John E. Sylvester

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Sylvester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Sylvester. The network helps show where John E. Sylvester may publish in the future.

Co-authorship network of co-authors of John E. Sylvester

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Sylvester. A scholar is included among the top collaborators of John E. Sylvester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Sylvester. John E. Sylvester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial 2020 ·European Urology ·David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence I. Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, Hongliang Shi, Zhan Ye, Hélène M. Faessel, Huamao Mark Lin, Yanyan Zhu, Fred Saad, David B. MacLean, Neal D. Shore	50
2	Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC) 2016 ·Annals of Oncology ·David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence I. Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, David B. MacLean, Serap Sankoh, Hélène M. Faessel, Huamao Mark Lin, Neal D. Shore	7
3	Optimal Equations for Describing the Relationship Between Prostate Volume, Number of Sources, and Total Activity in Permanent Prostate Brachytherapy 2010 ·American Journal of Clinical Oncology ·Jesse N. Aronowitz, Jeff M. Michalski, Gregory S. Merrick, John E. Sylvester, Juanita Crook, Wayne M. Butler, (unknown), David Pratt, (unknown), (unknown)	5
4	Fifteen-Year Biochemical Relapse-Free Survival, Cause-Specific Survival, and Overall Survival Following I125 Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience 2010 ·International Journal of Radiation OncologyBiologyPhysics ·John E. Sylvester, Peter Grimm, (unknown), Robert W. Galbreath, Gregory S. Merrick, John C. Blasko	131
5	Permanent prostate brachytherapy preplanned technique: The modern Seattle method step-by-step and dosimetric outcomes 2009 ·Brachytherapy ·John E. Sylvester, Peter Grimm, Stephen M. Eulau, (unknown), (unknown)	26
6	First Report on the Use of a Thinner I125 Radioactive Seed within 20 Gauge Needles for Permanent Seed Prostate Brachytherapy: Evaluation of Post-implant Dosimetry and Acute Toxicity 2009 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), John E. Sylvester, Peter Grimm, (unknown)	2
7	Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: Clinical and cost-utility analyses 2008 ·Urologic Oncology Seminars and Original Investigations ·Martin M. Quigley, Timothy P. Mate, John E. Sylvester	18
8	Inter-institutional variation of implant activity for permanent prostate brachytherapy 2008 ·Brachytherapy ·Jesse N. Aronowitz, Juanita Crook, Jeff M. Michalski, John E. Sylvester, Gregory S. Merrick, (unknown), David Pratt, (unknown), Wayne M. Butler, (unknown)	11
9	Second malignancies after prostate brachytherapy: Incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up 2006 ·International Journal of Radiation OncologyBiologyPhysics ·Stanley L. Liauw, John E. Sylvester, Christopher G. Morris, John C. Blasko, Peter Grimm	101
10	High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer 2006 ·Brachytherapy ·John E. Sylvester	1
11	15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience 2006 ·International Journal of Radiation OncologyBiologyPhysics ·John E. Sylvester, Peter Grimm, John C. Blasko, Jeremy Millar, Peter F. Orio, (unknown), Robert W. Galbreath, Gregory S. Merrick	153
12	Technical improvement in permanent seed implantation: a two-stage brachytherapy system. Description and comparison with current technique 2004 ·Brachytherapy ·Peter Grimm, John C. Blasko, John E. Sylvester, (unknown), (unknown), John Quackenbush, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David H. Wahl	14
13	Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience 2003 ·International Journal of Radiation OncologyBiologyPhysics ·John E. Sylvester, John C. Blasko, Peter Grimm, R. Meier, Judith A. Malmgren	130
14	Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes 2002 ·Seminars in Radiation Oncology ·John C. Blasko, (unknown), John E. Sylvester, Peter Grimm, William Cavanagh	149
15	10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy 2001 ·International Journal of Radiation OncologyBiologyPhysics ·Peter Grimm, John C. Blasko, John E. Sylvester, R. Meier, William Cavanagh	346
16	Palladium-103 brachytherapy for prostate carcinoma 2000 ·International Journal of Radiation OncologyBiologyPhysics ·John C. Blasko, Peter Grimm, John E. Sylvester, (unknown), (unknown), William Cavanagh	223
17	Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma 1997 ·Cancer ·Haakon Ragde, John C. Blasko, Peter Grimm, Gerald M. Kenny, John E. Sylvester, (unknown), (unknown), William Cavanagh	215
18	SHOULD BRACHYTHERAPY BE CONSIDERED A THERAPEUTIC OPTION IN LOCALIZED PROSTATE CANCER? 1996 ·Urologic Clinics of North America ·John C. Blasko, Haakon Ragde, (unknown), John E. Sylvester, William Cavanagh, Peter Grimm	98
19	Postoperative irradiation for the prevention of heterotopic bone: Analysis of different dose schedules and shielding considerations 1990 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Bert J. Thomas, Luu Tran, Michael T. Selch, John E. Sylvester, Robert G. Parker	35
20	The use of postoperative irradiation for the prevention of heterotopic bone formation after total hip replacement 1988 ·International Journal of Radiation OncologyBiologyPhysics ·John E. Sylvester, Peter Greenberg, Michael T. Selch, Bert J. Thomas, Harlan C. Amstutz	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact